VaxGen ends collaboration with EndoBiologics

By Lisa Kerner

Erie, Pa., May 30 - VaxGen, Inc. said it is ending its collaboration with EndoBiologics International Corp.

In May 2005, VaxGen agreed to fund proof-of-concept studies and determine possible commercial development of the vaccine candidate, while EndoBiologics conducted pre-clinical testing.

"Although we do not wish to pursue commercial development of this product, we will continue to look for other opportunities to develop a vaccine candidate against meningitis B," VaxGen president and chief executive officer Lance K. Gordon said in a company news release.

VaxGen is a biopharmaceutical company based in Brisbane, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.